期刊文献+

胃镜活检与胃腺癌切除术病理标本中表皮生长因子表达分析

Expression Analysis of Epidermal Growth Factor in Pathological Specimens of Gastroscopic Biopsy and Gastric Adenocarcinoma Resection
下载PDF
导出
摘要 目的:探讨胃镜活检和胃腺癌切除术病理标本中表皮生长因子(HER2/neu)表达的一致性。方法:收集2017年1月-2019年12月江苏省人民医院分院宿迁市第一人民医院消化内科收治的186例胃腺癌初诊患者,所有患者接受术前内镜活检及胃腺癌切除术治疗。对术前活检标本和术后病理标本采用免疫组织化学法测定HER2蛋白水平表达,采用荧光原位杂交技术测定HER2基因扩增情况。比较分析检测结果。结果:内镜活检标本阳性比例为13.44%;胃腺癌切除术后病理标本中阳性比例为15.05%。161例内镜活检标本为HER2过表达为阴性的病例中,有3例诊断为HER2过表达阳性,内镜活检标本和术后病理标本HER2表达一致性为98.14%,一致性检验Kappa值为0.936(P<0.05),两者检出的HER2表达一致性较好。结论:胃镜活检和胃腺癌切除术病理标本HER2/neu表达具有较好的一致性。 Objective:To investigate the consistency of epidermal growth factor(HER2/neu)expression in pathological specimens of gastroscopic biopsy and gastric adenocarcinoma resection.Methods:From January 2017 to December 2019,186 newly diagnosed patients with gastric adenocarcinoma who were admitted to the Department of Gastroenterology,Suqian First People's Hospital,Jiangsu Provincial People's Hospital Branch were collected.All patients received preoperative endoscopic biopsy and gastric adenocarcinoma resection.The expression of HER2 protein was detected by immunohistochemistry in preoperative biopsy specimens and postoperative pathological specimens,and HER2 gene amplification was detected by fluorescence in situ hybridization.Comparative analysis of test results.Results:The positive rate of endoscopic biopsy specimens was 13.44%.The positive rate of pathological specimens after gastric adenocarcinoma resection was 15.05%.Of the 161 cases with endoscopic biopsy specimens negative for HER2 overexpression,3 were diagnosed as positive for HER2 overexpression.The consistency of HER2 expression between endoscopic biopsy specimens and postoperative pathological specimens was 98.14%,and the Kappa value of the consistency test was 0.936(P<0.05).The HER2 expression detected by the two methods was in good agreement.Conclusion:The expression of HER2/neu in the pathological specimens of gastroscopic biopsy and gastric adenocarcinoma resection has good consistency.
作者 王艳 王利利 Wang Yan;Wang Li-li(Department of Gastroenterology,Suqian First People's Hospital,Branch of Jiangsu Provincial People's Hospital,Suqian 223800,Jiangsu Province,China)
出处 《中外医药研究》 2022年第2期144-146,共3页 JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词 胃腺癌 胃镜 病理标本 表皮生长因子 Gastric adenocarcinoma Gastroscope Pathological specimen Epidermal growth factor
  • 相关文献

参考文献5

二级参考文献40

  • 1Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16(2) :273-278.
  • 2Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 3Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 ( 3 ) :487-493.
  • 4Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 ( HER2 )-positive advanced gastric cancer ( GC ). J Clin Oncol, 2009, 27 : 18S( suppl : abstr LBA4509 ).
  • 5Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742) :687-697.
  • 6Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7) :797-805.
  • 7Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe, 2010, 31 ( 3 ) :208-217.
  • 8RuschoffJ, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457 ( 3 ) : 299-307.
  • 9Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol, 2011, In press.
  • 10Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro- oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5 ) and two in situ hybridization methods ( FISH and SISH). Histopathology, 2011, 58 ( 3 ) : 383-394.

共引文献155

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部